Reuters logo
BRIEF-Alkermes says FDA approves two-month ARISTADA for treatment of schizophrenia
June 6, 2017 / 1:56 PM / in 6 months

BRIEF-Alkermes says FDA approves two-month ARISTADA for treatment of schizophrenia

June 6 (Reuters) - Alkermes plc:

* FDA approves two-month ARISTADA® for treatment of schizophrenia

* New two-month dose is expected to be available in mid-June

* Says new two-month dose of ARISTADA is expected to be available in mid-June Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below